The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

@article{Nuechterlein2008TheMC,
  title={The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.},
  author={Keith H. Nuechterlein and Michael F. Green and Robert S Kern and Lyle E. Baade and Deanna M. Barch and Jonathan D. Cohen and Susan M. Essock and Wayne S. Fenton and Frederick J. Frese and James M. Gold and Terry E. Goldberg and Robert K Heaton and Richard S. E. Keefe and Helena C. Kraemer and Raquelle I. Mesholam-Gately and Larry J. Seidman and Ellen L. Stover and Daniel R. Weinberger and Alexander S. Young and Steven J. Zalcman and Stephen R. Marder},
  journal={The American journal of psychiatry},
  year={2008},
  volume={165 2},
  pages={
          203-13
        }
}
OBJECTIVE The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of… 

Tables from this paper

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

OBJECTIVE The consensus cognitive battery developed by the National Institute of Mental Health's (NIMH's) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

The current findings offer the initial steps to identify functionally meaningful co-primary measures in this area and will help to guide further evaluation of such measures.

Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia

Reliability and validity of the NeuroCognitive Performance Test, a web-based neuropsychological assessment

The reliability and validity of the NCPT battery as a measure of cognitive performance are demonstrated and support the feasibility of web-based, unsupervised testing, with potential utility in clinical and research settings.

The MATRICS consensus cognitive battery: what we know 6 years later.

Recent results regarding the test qualities of the MCCB when used in multisite clinical trials, its sensitivity to treatment effects, and its covariation with biomarkers are summarized.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

The MCCB is a cognitive assessment battery composed of ten instruments, which assess the seven domains in a little over one hour, and has been standardized in U.S. population, and the Spanish standardization has been recently published.

Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia

An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder

An evaluation of the clinical efficacy of the MATRICS Consensus Cognitive Battery and the tests recommended by the International Society for Bipolar Disorders in a BD cohort were the aims of the current study.
...

References

SHOWING 1-10 OF 53 REFERENCES

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

OBJECTIVE The consensus cognitive battery developed by the National Institute of Mental Health's (NIMH's) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative

NIMH-MATRICS survey on assessment of neurocognition in schizophrenia

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.

The current findings offer the initial steps to identify functionally meaningful co-primary measures in this area and will help to guide further evaluation of such measures.

Identification of separable cognitive factors in schizophrenia

Direct assessment of functional abilities: relevance to persons with schizophrenia

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS

Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects

This issue of Psychopharmacology presents a set of review articles derived from a meeting organized by the Neuropharmacology Committee of the measurement and treatment research to improve cognition in schizophrenia, designed to achieve broad academic and industry consensus regarding the nature of cognitive impairments in schizophrenia.

Attentional vulnerability indicators, thought disorder, and negative symptoms.

Results are consistent with the view that signal-discrimination deficits in situations demanding high levels of effortful processing are enduring vulnerability factors for schizophrenic negative symptoms and possibly for certain schizophrenic forms of thought disorder.
...